FDA grants priority review to durvalumab plus enfortumab vedotin for MIBC
FDA action · Renal & Urology News · 2026-10-02. Number 4 in the UrologyWatch Top 5 for October 4, 2026.
The FDA has granted priority review to a combination regimen of durvalumab and enfortumab vedotin for muscle-invasive bladder cancer, a regulatory step already reported for the same combination in the metastatic setting.
Why it matters: If approved for MIBC, this would extend the regimen into earlier-stage perioperative treatment.
Source: Renal & Urology News
Loading today's edition…